Skip to content
OpenCapital
Get started

Immunovant, Inc. IMVT Q4 2025 Annual earnings

Reported May 29, 2025 · Before market open

Diluted EPS-$0.64Beat by $0.07
EPS estimate-$0.71

Next report

Aug 10, 2026 (In 4 weeks)
EPS estimate-$0.66

Financials

Q4 2025

Income statement

See full
Net income-$106.4M-41.3%
EPS (diluted)-$0.63-21.2%

Balance sheet

See full
Cash & equivalents$714.0M+12.4%
Total debt$98.0K-29.0%
Total equity$707.4M+14.5%
Total assets$776.2M+16.5%

Cash flow

See full
Operating cash flow-$110.6M-85.3%
CapEx$201.0K+34.0%
Free cash flow-$110.8M-85.2%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$2.9B-37.8%
Enterprise value$2.19B-45.7%

Returns & leverage

See full
Return on equity-62.5%+13.7pp
Debt / equity0×0.0×
Current ratio11.2×-2.5×

Versus estimates

Diluted EPS

Q4 2026-$0.73Miss by $0.13Q3 2026-$0.61Beat by $0.11Q2 2026-$0.73Miss by $0.01Q1 2026-$0.60Beat by $0.09
Q4 2025-$0.64Beat by $0.07
Q3 2025-$0.76Miss by $0.03

Ask the moment Immunovant, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Immunovant, Inc. report Q4 2025 earnings?
Immunovant, Inc. (IMVT) reported Q4 2025 earnings on May 29, 2025 before market open.
What were Immunovant, Inc.'s Q4 2025 revenue and EPS?
Immunovant, Inc. reported diluted EPS of $-0.64 for Q4 2025.
Did Immunovant, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.71 by $0.07.
How did Immunovant, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 23.1% from $-0.52.
Where can I find Immunovant, Inc.'s Q4 2025 SEC filings?
You can read the 10-K periodic report (0001764013-25-000092) directly on SEC EDGAR. The filing index links above go to sec.gov.